Proprietary Portfolio

The continued success of its partnered discovery segment provides MorphoSys with the adequate resources to channel substantial investment into proprietary R&D. Its in-house development organization focuses on the development of promising therapeutic antibody candidates in the area of inflammation and oncology. Learn more about the our programs which are in clinical evaluation:

Clinical Programs

Tafasitamab (MOR208)

MOR208 (tafasitamab) has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.
Further Information


In preclinical studies, MOR202 mediated antibody-dependent cell-mediated cytotoxicity in MM cells derived from patients in vitro.
Further Information

Otilimab (MOR103/GSK3196165)

Otilimab (MOR103/GSK3196165) is a fully human HuCAL antibody directed against GM-CSF (granulocytemacrophage-colony stimulating factor). MOR103 is being developed in the area of inflammatory diseases.
Further Information


MOR106 is a human IgG1 monoclonal antibody for treatment of inflammatory diseases.
Further Information

Physicians and Patients

Physicians interested in learning more about MorphoSys-sponsored clinical trials should contact:

Patients are kindly asked to contact their treating physicians if they are interested in participating in any of MorphoSys's clinical trials.

MorphoSys’s product candidates are investigational and are currently not approved for the treatment of any disease or condition anywhere in the world. They cannot be prescribed or purchased for therapy at present.
The MorphoSys website may contain information on drug candidates and clinical trials sponsored by MorphoSys with the intention of increasing the transparency of the company’s clinical research.
Information contained within this website is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment.
All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of information available through the site. MorphoSys may amend the information at any time without notice.